Rein Therapeutics Inc. (RNTX) 10-Year Financial Performance & Capital Metrics

RNTX • • Industrial / General

HealthcarePharmaceuticalsBiopharmaceutical R&DOncology Therapeutics

AboutRein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.Show more

Revenue $0
EBITDA -$65M -402505.7%
Net Income -$63M -399614.0%
EPS (Diluted) -3.51 -2.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -205.24% -166351.8%
ROIC -313.55% -39509.8%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 13 (bottom 13%)
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-903.08%

EPS CAGR

10Y-

5Y-

3Y-

TTM-80426.6%

ROCE

10Y Avg-15.85%

5Y Avg-15.85%

3Y Avg-26.33%

Latest-78.87%

Peer Comparison

Oncology Therapeutics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
HCMHUTCHMED (China) Limited	2.63B	15.31	69.59	-24.8%	77.53%	37.59%	0.12
SHPHShuttle Pharmaceuticals Holdings, Inc.	2.85M	1.48	-0.00			-7.68%	1.65
BGMSBio Green Med Solution, Inc.	7.01M	1.43	-0.00	-89.76%	-67.15%	-76.65%
SBFMSunshine Biopharma, Inc.	5.99M	1.22	-0.17	44.75%	-17.35%	-24.55%	0.04
RNTXRein Therapeutics Inc.	30.49M	1.16	-0.33			-127.48%
CGEMCullinan Therapeutics, Inc.	629.75M	10.66	-3.43			-48.03%	0.00
ONCBeOne Medicines Ltd.	34.44B	338.29	-55.28	54.96%	1.38%	1.66%	0.32

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-
Gross Profit+	0	0	0	0	0
Gross Margin %	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-
Operating Expenses+	20.5K	26.61K	27.65K	16.28K	65.11M
OpEx % of Revenue	-	-	-	-	-
Selling, General & Admin	9.33K	9.6K	9.68K	11.36K	13.86M
SG&A % of Revenue	-	-	-	-	-
Research & Development	11.17K	17.01K	17.97K	3.99K	14.25M
R&D % of Revenue	-	-	-	-	-
Other Operating Expenses	0	0	0	928	37M
Operating Income+	-20.5K	-26.61K	-27.65K	-16.28K	-65.11M
Operating Margin %	-	-	-	-	-
Operating Income Growth %	-	-0.3%	-0.04%	0.41%	-3999.49%
EBITDA+	-20.33K	-26.48K	-27.48K	-16.16K	-65.05M
EBITDA Margin %	-	-	-	-	-
EBITDA Growth %	-	-0.3%	-0.04%	0.41%	-4025.06%
D&A (Non-Cash Add-back)	163	121	169	119	63K
EBIT	-20.5K	-26.61K	-27.65K	-15.35K	-28.11M
Net Interest Income+	0	0	0	600	400K
Interest Income	0	0	0	600	400K
Interest Expense	0	0	0	0	0
Other Income/Expense	-661	441	318	544	800K
Pretax Income+	-21.16K	-26.16K	-27.33K	-15.73K	-64.31M
Pretax Margin %	-	-	-	-	-
Income Tax+	0	0	0	0	-1.54M
Effective Tax Rate %	1%	1%	1%	1%	0.98%
Net Income+	-21.16K	-26.16K	-27.33K	-15.73K	-62.88M
Net Margin %	-	-	-	-	-
Net Income Growth %	-	-0.24%	-0.04%	0.42%	-3996.14%
Net Income (Continuing)	-21.16K	-26.16K	-27.33K	-15.73K	-62.77M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.00	-5.89	-6.02	-3.42	-3.51
EPS Growth %	-	-	-0.02%	0.43%	-0.03%
EPS (Basic)	-0.00	-5.89	-6.02	-3.42	-3.51
Diluted Shares Outstanding	17.43M	4.44K	4.54K	4.6K	17.94K
Basic Shares Outstanding	17.43M	4.44K	4.54K	4.6K	17.94K
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	16.33M	48.18M	21.87M	18.27M	13.66M
Cash & Short-Term Investments	13.8M	45.93M	21.24M	17.31M	12.87M
Cash Only	7.05M	3.6M	5.19M	17.31M	12.87M
Short-Term Investments	6.76M	42.33M	16.05M	0	0
Accounts Receivable	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	593K	25K	631K	746K	676K
Total Non-Current Assets+	15K	304K	134K	87.74M	55.58M
Property, Plant & Equipment	15K	280K	110K	19K	1K
Fixed Asset Turnover	-	-	-	-	-
Goodwill	0	0	0	6.33M	0
Intangible Assets	0	0	0	79.2M	48.53M
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	0	24K	24K	2.19M	2K
Total Assets+	16.34M	48.48M	22.01M	106.01M	69.24M
Asset Turnover	-	-	-	-	-
Asset Growth %	-	1.97%	-0.55%	3.82%	-0.35%
Total Current Liabilities+	3.96M	4.51M	3.38M	4.38M	5.75M
Accounts Payable	1.6M	1.21M	1.72M	1.19M	911K
Days Payables Outstanding	-	-	-	-	-
Short-Term Debt	168K	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	243K	60K	181K	206K	3.36M
Current Ratio	4.12x	10.69x	6.46x	4.17x	2.38x
Quick Ratio	4.12x	10.69x	6.46x	4.17x	2.38x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	219K	69K	0	94.74M	9.1M
Long-Term Debt	219K	0	0	0	0
Capital Lease Obligations	0	69K	0	0	0
Deferred Tax Liabilities	0	0	0	3.33M	8.82M
Other Non-Current Liabilities	0	0	0	91.41M	277K
Total Liabilities	4.18M	4.58M	3.38M	99.12M	14.85M
Total Debt+	387K	162K	33K	48K	0
Net Debt	-6.66M	-3.44M	-5.16M	-17.27M	-12.87M
Debt / Equity	0.03x	0.00x	0.00x	0.01x	-
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-	-	-	-	-
Total Equity+	12.16M	43.9M	18.62M	6.89M	54.39M
Equity Growth %	-	2.61%	-0.58%	-0.63%	6.9%
Book Value per Share	0.70	9887.54	4102.60	1497.59	3032.22
Total Shareholders' Equity	12.16M	43.9M	18.62M	6.89M	54.39M
Common Stock	44K	91K	91K	91K	108K
Retained Earnings	-219.29M	-245.46M	-272.79M	-288.52M	-351.4M
Treasury Stock	0	0	0	0	0
Accumulated OCI	-2K	-13K	-48K	-63K	-18K
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-20.48M	-23.75M	-24.86M	-19.81M	-22.29M
Operating CF Margin %	-	-	-	-	-
Operating CF Growth %	-	-0.16%	-0.05%	0.2%	-0.13%
Net Income	-21.16M	-26.16M	-27.33M	-15.73M	-62.88M
Depreciation & Amortization	163K	121K	169K	119K	63K
Stock-Based Compensation	1.89M	2.26M	2.08M	1.19M	1.12M
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	-95K	-213K	-208K	-4K	37M
Working Capital Changes	-1.28M	242K	420K	-5.38M	2.41M
Change in Receivables	0	0	0	0	0
Change in Inventory	0	0	0	0	0
Change in Payables	116K	-386K	510K	-4.98M	-279K
Cash from Investing+	6.41M	-35.92M	26.46M	16.2M	0
Capital Expenditures	-5K	-157K	0	0	0
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	208K	66K	0	42K	0
Cash from Financing+	15.8M	55.66M	0	15.79M	17.82M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	0	74K	0	15.79M	7.17M
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-20.48M	-23.91M	-24.86M	-19.81M	-22.29M
FCF Margin %	-	-	-	-	-
FCF Growth %	-	-0.17%	-0.04%	0.2%	-0.13%
FCF per Share	-1.17	-5384.95	-5477.70	-4307.29	-1242.67
FCF Conversion (FCF/Net Income)	967.81x	907.89x	909.84x	1259.09x	0.35x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-0.17%	-0.09%	-0.09%	-0.12%	-205.24%
Return on Invested Capital (ROIC)	-	-0.09%	-0.08%	-0.79%	-313.55%
Debt / Equity	0.03x	0.00x	0.00x	0.01x	-
FCF Conversion	967.81x	907.89x	909.84x	1259.09x	0.35x

Frequently Asked Questions

Growth & Financials

Rein Therapeutics Inc. (RNTX) grew revenue by 0.0% over the past year. Growth has been modest.

Rein Therapeutics Inc. (RNTX) reported a net loss of $58.9M for fiscal year 2024.

Dividend & Returns

Rein Therapeutics Inc. (RNTX) has a return on equity (ROE) of -205.2%. Negative ROE indicates the company is unprofitable.

Rein Therapeutics Inc. (RNTX) had negative free cash flow of $21.0M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener